These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34225766)

  • 21. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
    Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
    J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
    Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
    Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma.
    Chen X; Li X; Liu Y; Zhang Z; Zhang X; Huang J; Li H; Li F; Zhang L; Li L; Wu X; Ma W; Sun Z; Yu H; Zhou Z; Feng X; Cui K; Li Z; Zhang H; Zeng Y; Wan X; Chen YH; Zhang M; Zhang Y
    Immunotherapy; 2020 Jul; 12(10):681-696. PubMed ID: 32580597
    [No Abstract]   [Full Text] [Related]  

  • 24. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
    N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
    Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
    Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
    Ying Z; Yang H; Guo Y; Li W; Zou D; Zhou D; Wang Z; Zhang M; Wu J; Liu H; Zhang P; Yang S; Zhou Z; Zheng H; Song Y; Zhu J
    Cancer Med; 2021 Feb; 10(3):999-1011. PubMed ID: 33382529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Dubnikov Sharon T; Assayag M; Avni B; Kfir-Erenfeld S; Lebel E; Gatt ME; Goldschmidt N; Stepensky P; Asherie N; Grisariu S
    Br J Haematol; 2023 Jul; 202(1):74-85. PubMed ID: 37070396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
    Wang Y; Zhang WY; Han QW; Liu Y; Dai HR; Guo YL; Bo J; Fan H; Zhang Y; Zhang YJ; Chen MX; Feng KC; Wang QS; Fu XB; Han WD
    Clin Immunol; 2014 Dec; 155(2):160-75. PubMed ID: 25444722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.
    Wang T; Gao L; Wang Y; Zhu W; Xu L; Wang Y; Yue W; Tang G; Chen L; Chen J; Zhang W; Yu X; Feng D; Yang J
    Immunotherapy; 2020 Sep; 12(13):997-1006. PubMed ID: 32752910
    [No Abstract]   [Full Text] [Related]  

  • 31. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
    Nagler A; Perriello VM; Falini L; Falini B
    Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Chen X; Qin Y; Xue X; Xie Z; Xie T; Huang L; Zhu H; Gao L; Li J; Yang J; Gui L; Yang S; Chen H; Feng X; Shi Y
    Cancer Immunol Immunother; 2024 Oct; 73(12):250. PubMed ID: 39358470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
    Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
    Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
    Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
    Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ
    Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
    Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma].
    Yu T; Liu H; Lei W; Chen PP; Zhao AQ; Yuan XG; Gao JM; Qian WB
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):820-824. PubMed ID: 38049333
    [No Abstract]   [Full Text] [Related]  

  • 38. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
    Tu S; Zhou X; Guo Z; Huang R; Yue C; He Y; Li M; Chen Y; Liu Y; Chang LJ; Li Y
    Front Oncol; 2019; 9():1350. PubMed ID: 31867275
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.